Novel Test for Heart Problems to be Launched at Healthcare Innovation Expo 2013

The test is non-invasive, takes 15 minutes and uses an arm cuff much like a blood pressure test. However, this test can detect signs of early onset cardiovascular disease. It measures the functional health of endothelial cells in the brachial artery of the arm which independent research has shown to be a very reliable indicator of cardiovascular health.

"We have received approval to add the CE mark to our novel medical device,” says Steve Everist, CEO of Everist Health. "The CE mark opens up the market for this device to countries in the European Union and to other countries that recognize the CE mark. Use of the test will help to save lives through the early detection of cardiovascular disease, particularly in asymptomatic individuals, i.e., young people who are fit, non-smokers and have no family history of heart problems.”

“At the same time, because early detection of potential heart problems has the ability to reduce health care costs, we believe this test will appeal to government and private health care providers. Heart disease is the biggest single killer of both men and women in Europe, North America, and elsewhere in the world.”

Everist Health is introducing the AngioDefender at the Healthcare Innovation Expo 2013, where it hopes to meet potential UK partners in both the government and private sector. Following its UK introduction, the Company also expects to seek distributors for its technology throughout the European Union.

“We chose to launch the AngioDefender at the NHS Healthcare Innovation Expo because we believe the Expo provides the best possible showcase for a novel device that can both lower health costs and improve patient outcomes,” says Steve Everist. The NHS Healthcare Innovation Expo will be held at ExCeL London Convention Centre, located at the London Royal Docks. Everist Health, Inc. will be located at Stand D-02.

About Everist Health

Everist Health, Inc. is a personalized medicine company, which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Everist Health is focused on rapidly growing disease areas with major unmet needs, including cancer, cardiovascular disease and metabolic disease (e.g. diabetes). EGI’s innovative products successfully integrate with mobile digital services, smartphones and tablet computers resulting in advanced medical technology which, until now, has been confined to the hospital setting. For online information about Everist Health, please visit For more specific information about Everist Health European marketing, please contact Randal Charlton at 0148-328-4321 or Vicki Theisen at This email address is being protected from spambots. You need JavaScript enabled to view it..

Learn more about what we can do for you